Barr Fires Back At Celgene In Thalomid Patent Case
In the latest salvo over generic versions of the cancer drug Thalomid, generic-drug maker Barr Laboratories Inc. said on Thursday that Celgene Corp.'s patent claims are unenforceable because the inventor withheld...To view the full article, register now.
Already a subscriber? Click here to view full article